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http://www.cellandbioscience.com/content/4/1/41RESEARCH Open AccessPinocembrin suppresses TGF-β1-induced epithelial-
mesenchymal transition and metastasis of human
Y-79 retinoblastoma cells through inactivating
αvβ3 integrin/FAK/p38α signaling pathway
Kun-Shiang Chen1, Ming-Der Shi2,3, Chi-Sheng Chien4 and Yuan-Wei Shih5,6*Abstract
Background: Pinocembrin is the most abundant flavonoid in propolis. In this study, we investigated the antimetastatic
effect of pinocembrin on TGF-β1-induced epithelial-mesenchymal transition (EMT) and metastasis of human Y-79
retinoblastoma cells.
Results: Firstly, the results showed that pinocembrin significantly suppresses the TGF-β1-induced abilities of the
invasion and migration of Y-79 cells under non-cytotoxic concentration. Pinocembrin decreased TGF-β1-induced
expression of vimentin, N-cadherin, αv and β3 integrin in Y-79 cells. Molecular data also showed pinocembrin
inhibits the activation of focal adhesion kinase (FAK) and p38α signal involved in the downregulation of enzyme
activities, protein and messenger RNA levels of matrix metalloproteinase-2/9 (MMP-2/-9) induced by TGF-β1. Next,
pinocembrin also strongly inhibited the degradation of inhibitor of kappaBα (IκBα) and the nuclear levels of nuclear
factor kappa B (NF-κB). Also, a dose-dependent inhibition on the binding ability of NF-κB was further observed under
pinocembrin treatment.
Conclusions: Presented results indicated that pinocembrin inhibits TGF-β1-induced epithelial-mesenchymal transition
(EMT) and metastasis of Y-79 cells by inactivating the αvβ3 integrin/FAK/p38α signaling pathway. Thus, our findings
point to the anticancer potential of pinocembrin against retinoblastoma cells.
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Retinoblastoma is the most common primary intraocular
tumor in children (0–5 years). In the United States, this
disease presents most frequently as unilateral sporadic
tumors and less frequently as bilateral hereditary tumors.
There are two types of this disease, the genetic-heritable
type and non-genetic-non-heritable type. About 55 percent
of children with retinoblastoma have the non-genetic
type. Children with the inherited form have a high risk
of developing other cancers later in life. If untreated,* Correspondence: shih723@seed.net.tw
5Department of Food Nutrition, Chung Hwa University of Medical
Technology, Tainan 71703, Taiwan
6Department of Biological Science and Technology and Graduate Institute of
Biomedical Science, Chung Hwa University of Medical Technology, Tainan
71703, Taiwan
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the patients die of intracranial extension and disease
dissemination within two years [1]. Human retinoblastoma
exhibits the patterns of invasion and metastasis. Direct
invasive spreads along the optic nerve to the brain and
can also seed the orbital tissue and adjacent bone [2].
Current treatments include enucleation, external beam
radiotherapy, cryotherapy, photocoagulation photocoagu-
lation, and chemotherapy [3]. Although these methods
achieve survival rates of over 95%, there remains a need
for better treatment alternatives to improve visual results
and to avoid enucleation in hereditary retinoblastoma
[4-6]. Thus, effective chemopreventive treatment for
metastasis would have an important impact on retino-
blastoma mortality rates.
The metastasis of tumor cells is a complex, multistage
process. To facilitate the cell motility, invading cells needtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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extracellular matrix (ECM) environment, suppress anoikis
and reorganize their cytoskeletons [7]. Integrins are a
family of transmembrane adhesion receptors comprised
of 19α and 8β subunits that interact non-covalently to
form up to 24 different heterodimeric receptors. Integ-
rin binds to ECM proteins or integrin cross-linking
increases the tyrosine phosphorylation of FAK [8]. FAK
is a nonreceptor tyrosine kinase primarily localized to
cell-matrix adhesions which acts as a central regulator
of focal adhesion influencing cell survival, differenti-
ation, proliferation, migration and tissue remodeling
[9-11]. Once localized to sites of transmembrane integ-
rin receptor clustering, tyrosine-phosphorylated FAK
plays an important role in signal transduction triggered
by diverse extracellular signals [12] and represents a
convergent point for synergistic interaction between signal
pathways activated by growth factors and integrins
[13-15]. Recently a conjunction between cancer stem
cells and epithelial-mesenchymal transition (EMT) has
been reported, and it has been shown that morphological
and molecular changes occur when epithelial cells lose
their characteristics, gain mesenchymal properties, and
become motile, playing a critical role in the invasion of
cancer cells [16,17]. The expression of Snail (Snail1),
Slug (Snail2), ZEB1 or Twist, along with the expression
of mesenchymal markers such as N-cadherin and
vimentin, and the loss of E-cadherin are key molecular
markers of EMT [18]. Transforming growth factor
beta-1 (TGF-β1) has been identified as the main in-
ducer of tumor EMT. The TGF-β1 is a pleiotropic
cytokine that can mediate a wide spectrum of cellular
effects through a variety of signaling pathways. Several
studies have reported that TGF-β1 can promote an-
giogenesis, facilitate invasion, and suppress the host
immune system [19].
Pinocembrin (5,7-dihydroxyflavanone, Figure 1A) is a
water insoluble flavonoid in propolis which is extracted
as a pure compound. It is also found in nut pines, euca-
lyptus leaves and acacia gum. Now pinocembrin can be
procured by synthesis and therefore is in abundance
[20]. Pinocembrin has been shown to possess extensive
pharmacological effects including antimicrobial [21,22],
antioxidant [23], anti-mutagenic, and anti-inflammatory
activities [24,25]. Although many studies have shown
that pinocembrin possess various biological proper-
ties, the mechanisms by which this compound acts
against cancers remain unclear. Based on our results,
we hypothesized that pinocembrin might have antime-
tastatic property. Thus, this study utilized TGF-β1 as an
inducer to induce the EMT of Y-79 retinoblastoma
cells, and investigated the antimetastatic effect of
pinocembrin on this cell model as well as its active
mechanisms.Methods
Reagents and antibodies
Pinocembrin (purity≧95%) was purchased from Extra-
synthese (Genay, France). Poly-D-lysine, DMSO, Tris–HCl,
EDTA, SDS, phenylmethylsulfonyl fluoride, bovine serum
albumin (BSA), gelatin, crystal violet, leupeptin, Nonidet
P-40, deoxycholic acid, sodium orthovanadate, mouse
monoclonal antibody specific for αvβ3 integrin, and a se-
lective αvβ3 integrin antagonist cyclic RGD (cycloRGDfV)
peptide were purchased from Sigma-Aldrich (St. Louis,
MO, USA); the protein assay kit was obtained from
Bio-Rad Laboratories (Hercules, CA, USA). Dulbecco’s
phosphate buffer solution (PBS), trypsin-EDTA, and RPMI
1640 medium were purchased from Life Technologies, Inc.
(Gibco/BRL, Gaithersburg, MD). Matrigel was purchased
from BD Biosciences (Bedford, MA). Antibodies against
E-cadherin, N-cadherin, vimentin, FAK, FAK (Tyr397,
Tyr576, Tyr925), ERK1/2, ERK1/2 (Thr202/Tyr204), JNK1/
2, JNK1/2 (Thr183/Tyr185), p38α, and p38α (Thr180/
Tyr182) were purchased from Cell Signaling Tech. (Beverly,
MA, USA). NF-κB (p50 and p65), β-actin, and C23 anti-
bodies were purchased from BD Transduction Laboratories
(San Diego, CA, USA). An enhanced chemiluminescence
(ECL) kit was purchased from Amersham GE Healthcare
UK Ltd (Buckinghamshire, England).
Cell culture and pinocembrin treatment
The human retinoblastoma Y-79 cell line was obtained
from BCRC (Bioresource Collection and Research Center
in Hsin-Chu, Taiwan). Cells were cultured at 37°C in a
humidified atmosphere of 5% CO2-95% air. In medium
supplemented with 10% fetal calf serum, 2 mM L-glu-
tamine, 1 mM sodium pyruvate, and antibiotics (100 U/
ml of penicillin and 100 mg/ml of streptomycin). Y-79
cells were grown in suspension at a concentration of
105-106 cells/ml. For all anti-metastatic examinations,
cells were cultured in poly-D-lysine-coated culture plates.
The stock solution of pinocembrin was dissolved in
dimethyl sulfoxide (DMSO) and sterilized by filtration
through 0.2 μm disc filters. Appropriate amounts of
stock solution (1 mg/ml in DMSO) of pinocembrin were
added to the cultured medium to achieve the indicated
concentrations (the final DMSO concentration was less
than 0.2%).
Cell viability assay
To evaluate the cytotoxicity of pinocembrin, a MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbro-
mide] assay was performed to determine the cell viability
[26]. Briefly, cells were seeded at a density of 4 × 104 cells/
ml in a 24-well plate for 24 h. Then, the cells were treated
with or without pinocembrin under various concentra-
tions for 24 h. Each concentration was repeated three
times. Also, to further investigate whether pinocembrin
Figure 1 The effect of pinocembrin on the viability and growth of Y-79 cells. (A) The chemical structure of pinocembrin. (B) Cultured cells
were treated with or without pinocembrin under various concentrations (0, 5, 10, 20, 40, 60, 80 and 100 μM) for 24 h. Thereafter, cell viability was
determined by MTT assay. (C) The cells were fixed and stained with PI, and the cell cycle distribution was then analyzed by flow cytometry (FACS).
(D) Cells were treated with or without of drugs (10 ng/ml TGF-β1 and 5 μM pinocembrin) for 24 h and the cell viability was determined by MTT assay.
Values represent mean ± SD of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 compared with the untreated control (dose 0).
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treated with the presence or absence of drugs (10 ng/ml
TGF-β1 and 5 μM pinocembrin) for 24 h. After the expos-
ure period, the medium was removed and followed by
washing of cells with PBS. Then, the medium was changed
and incubated with MTT solution (5 mg/ml)/well for 4 h.
The medium was removed, and formazan was solubilized
in isopropanol and measured spectrophotometrically at
563 nm. The percentage of viable cells was estimated by
comparing with the untreated control cells.
Flow cytometric assay
The effects of pinocembrin on Y-79 cell-cycle progression
and TGF-β1-induced avβ3 integrin expression were
determined by flow cytometry using FACScan (Becton
Dickinson Immunocytometry Systems, UK). Firstly, to
analyze the cell-cycle distribution, the cells were firsttreated with various concentrations of pinocembrin for
24 h, and then were collected by trypsinization, fixed in
75% absolute ethanol, washed in PBS, and resuspended
in 1 ml of PBS containing 0.5 mg/ml RNase A and
0.01 mg/ml propidium iodide (PI) in the dark for
30 min at room temperature. The cell-cycle profiles
were analyzed by a flow cytometer. The percentage of
cells in the sub-G1, G0/G1, S, and G2/M phases of the
cell cycle was analyzed by the ModFit LT 3.0 software
(Verity Software, Topsham, ME). Furthermore, the cell
surface expression of avβ3 integrin was determined
using flow cytometry. Y-79 cells were plated in six-well
dishes. The cells were then washed with PBS and detached
with trypsin at 37°C. Cells were fixed for 10 min in PBS
containing 1% paraformaldehyde. After rinsing in PBS,
the cells were incubated with a mouse anti-human anti-
body against avβ3 integrin (1:100) for 1 h at 4°C. Cells
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isothiocyanate-conjugated goat anti-rabbit secondary IgG
(1:100; Leinco Tec. Inc., St. Louis, MO, USA) for 45 min
and analyzed by flow cytometry.Cell-matrix adhesion assay
Y-79 cells were pretreated with 5 μg/ml anti-αvβ3 mono-
clonal antibody (mAb) or 80 nM cyclic RGD peptide
(cyclo-RGDfV) for 30 min and then stimulated with
10 ng/ml TGF-β1 in the presence or absence of 5 μM
pinocembrin for 24 h. Subsequently, cells were seeded
at a density of 1 × 105 cells/ml in a 24-well plate and
coated with 500 μl type IV collagen (10 μg/ml); then
they were cultured for 30 min. Then, non-adherent
cells were removed by PBS washes, and adherent cells
were fixed in ethanol. After staining with 0.1% crystal
violet, fixed cells were lysed in 0.2% Triton X-100, and
measured spectrophotometrically at 550 nm.Transwell invasion and migration assay
Invasion and migration assay were performed by using
Hanging Cell Culture-inserts (BD Biosciences, San Jose,
CA; pore size, 8-μm) in 6-well dishes. The ability of Y-79
cells to pass through filters coated with Matrigel (BD
Biosciences) was measured by invasion assay. Matrigel
was diluted to 200 μg/ml with filtered distill water and
applied to the upper surface of the filter inserts. Briefly,
Y-79 cells were pretreated with 5 μg/ml anti-αvβ3
monoclonal antibody (mAb) or 80 nM cyclic RGD pep-
tide (cyclo-RGDfV) for 30 min and then stimulated with
10 ng/ml TGF-β1 in the presence or absence of 5 μM
pinocembrin. After 24 h, cells were detached by trypsin
and resuspended in serum-free medium. Medium con-
taining 10% fetal bovine serum was applied to the lower
chamber as a chemoattractant, and then cells were
seeded on the upper filter at a density of 1 × 105 cells/ml
in the serum-free medium. The plates were incubated
for 24 h at 37°C in 5% CO2, filter inserts were removed
from the wells and the cells on the upper surface of the
filter were wiped with a cotton-tipped swab. Filters were
fixed with methanol for 10 min and stained with Giemsa
dye for 1 h, and then the cells that had invaded the
lower surface of the filter were counted under a light
microscope. The data are presented as the average
number of cells attached to the bottom surface from
randomly chosen fields. Each experiment was carried out
in triplicate. To measure the migration ability of Y-79
cells, cells were seeded into a transwell with 8 μm pore
polycarbonate filters which were not coated with matrigel.
Migrating cells were treated with the presence or absence
of drugs (TGF-β1 and pinocembrin). Migration assay was
measured as described in the invasion assay.Gelatin zymography assay
Cells (4 × 105 cells/ml) were seeded into the culture and
stimulated with 10 ng/ml TGF-β1 for 2 h and then
incubated in different concentrations of pinocembrin
(0, 1, 2.5, and 5 μM) for 24 h. Subsequently, the condi-
tioned medium was collected and gelatin zymography
was performed to examine the activities of MMP-2 and
MMP-9. Samples were mixed with loading buffer and
electrophoresed on 8% SDS-polyacrylamide gel containing
0.1% gelatin. Electrophoresis was performed at 140 and
110 V for 3 h. Gels were then washed twice in zymography
washing buffer (2.5% Triton X-100 in double-distilled
H2O) at room temperature to remove SDS, followed by
incubation at 37°C for 12–16 h in zymography reaction
buffer (40 mM Tris–HCl, 10 mM CaCl2, 0.02% NaN3),
stained with Coomassie blue R-250 (0.125% Coomassie
brilliant blue R-250, 0.1% amino black, 50% methanol,
10% acetic acid) for 1 h and destained with destaining
solution (20% methanol, 10% acetic acid, 70% double-
distilled H2O). Nonstaining bands representing the levels
of the latent forms of MMP-2 and MMP-9 were quanti-
fied by densitometer measurement using a digital imaging
analysis system.Isolation of total RNA, reverse transcriptase polymerase
chain reaction (RT-PCR) and DNA electrophoresis
Total RNA was isolated from human Y-79 cells using
the total RNA Extraction Midiprep System (Viogene
BioTek Corporation, Taiwan). Total RNA (2 μg) was
transcribed to 20 μl cDNA with 1 μl dNTPs (2.5 mM),
1 μl oligo dT (10 pmole/μl), 1 μl RTase (200 U), 1 μl
RNase inhibitor and 5 X reaction buffer. The appropriate
primers (sense of MMP-2, 5′-GGCCCTGTCACTCCT
GAGAT-3′ nt 1337–1356; antisense of MMP-2, 5′-GG
CATCCGGTTATCGGGGA-3′, nt 2026–2007; sense
of MMP-9, 5′-AGGCCTCTACAGAGTCTTTG-3′ nt
1201–1220; antisense of MMP-9, 5′-CAGTCCAACAA
GAAAGGACG-3′, nt 1700–1683; sense of GADPH,
5′-CGGAGTCAACGGATTGGTGTT-3′, nt 94–126;
antisense of 5′-AGCCTTCTCCATGGTTGGTGAAGAC-
3′, nt 399–375) were used for PCR amplifications. PCR
was performed with Platinum Taq polymerase (Invitrogen)
under the following conditions: 30 cycles of 94°C for
1 min, 59°C (MMP-2) or 60°C (MMP-9 and GAPDH) for
1 min, 72°C for 1 min followed by 10 min at 72°C.Western blotting assay
The preparation of cytosolic and nuclear fractions of the
cells was performed as described previously [27]. Western
blotting was performed as follows. The denatured sam-
ples (50 μg purified protein) were resolved on 10-12%
SDS-PAGE gels. The proteins were then transferred
onto nitrocellulose membranes. Non-specific binding of
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(TBS) containing 1% (w/v) nonfat dry milk and 0.1% (v/v)
Tween-20 (TBST) for more than 2 h. Membranes were
washed with TBST three times for 10 min and incubated
with an appropriate dilution of specific primary antibodies
in TBST overnight at 4°C. Subsequently, membranes were
washed with TBST and incubated with an appropriate
secondary antibody (horseradish peroxidase-conjugated
goat antimouse or antirabbit IgG) for 1 h. After wash-
ing the membrane three times for 10 min in TBST, the
bands detection was carried out by enhanced chemilumin-
escence using ECL Western blotting detection reagents
and exposed ECL hyperfilm in FUJFILM Las-3000 mini
(Tokyo, Japan). Then proteins were quantitatively deter-
mined by densitometry using FUJFILM-Multi Gauge V3.0
software.Electrophoretic mobility shift assay (EMSA)
Cell nuclear proteins were extracted with a nuclear extract
buffer and measured by electrophoretic mobility shift
assay (EMSA) [28]. Cells (1 × 105/ml) were collected in
PBS buffer (pH 7.4) and centrifuged at 2000 × g for 5 min
at 4°C. Cells were lysed with buffer A (10 mM HEPES,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.5 mM
PMSF (pH 7.9) containing 5% NP-40) for 10 min on ice,
and this was followed by vortexing to shear the cytoplas-
mic membranes. The lysates were centrifuged at 2000 × g
for 10 min at 4°C. The pellet containing the nuclei was
extracted with high salt buffer B (20 mM HEPES, 420 mM
NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF,
0.2 mM EDTA, and 25% glycerol) for 15 min on ice. The
lysates were centrifugated at 13000 × g for 10 min at 4°C.
The supernatant containing the nuclear proteins was
collected and frozen at −80°C until use. The protein
content of nuclear fractions was determined with Bio-Rad
protein assay. Synthetic double-strand oligonucleotides of
the consensus NF-κB binding sequence, 5′-AGTTGAGG
GGACTTTCCCAGGC-3′ and 3′-TCAACTCCCCTGAA
AGGGTCCG-5′, were 5′end- labeled with biotin. Binding
reactions containing 5 μg of nuclear proteins, double-
distilled H2O, 2 μl 10-fold binding buffer, 2 μg poly
(dI · dC) and 2 pmol oligonucleotide probe were incubated
for 15 min at room temperature. Specific competition
binding assays were performed by adding a 200-fold
excess of an unlabeled probe as a specific competitor.
Following formation of protein-DNA complexes, samples
were loaded on a 6% nondenaturing polyacrylamide gel in
0.5 × TBE buffer and then transferred to positively charged
nitrocellulose membranes (Millipore, Bedford, MA, USA)
by a transfer blotting apparatus and cross-linked in a
Stratagene crosslinker. Gel shifts were visualized with
streptavidin-horseradish peroxidase followed by chemi-
luminescent detection.Transient transfection and luciferase report gene assays
NF-κB transcriptional activity was measured by NF-κB-
luciferase report gene expression. Y-79 cells (4 × 104 cells/
well) were plated in six-well plates. The cells were transi-
ently co-transfected with the plasmids, pGL3-NF-κB,
pCMV-β-gal and pcDNA3.1 using Lipofectamine Plus
according to the manufacturer’s protocol. Briefly, a trans-
fection mixture containing 0.5 μg pGL3-NF-κB and 0.2 μg
pCMV-β-gal was mixed with the Lipofectamine Plus
reagent and added to the cells. After 8 h, the cells were
stimulated with 10 ng/ml TGF-β1 for 2 h and then
incubated in 5 μM pinocembrin for 0, 1, 3, 6, and 9 h.
Then the NF-κB-luciferase activity was measured accord-
ing to the manufacturer’s instructions (Promega). Briefly,
cells were washed twice with cold PBS and lysed by adding
100 μl 1X reporter lysis buffer (24 mM Tris–HCl
(pH 7.8), 2 mM dithiotreitol, 2 mM EDTA, 10% glycerol,
and 1% Triton X-100) (Promega, Madison, WI, USA).
After centrifugation (13000 × g, 2 min), samples were
measured for luciferase activity by using a Sirus Lumin-
ometer (Berthold Detection System; OAK Ridge, TN)
using 10 μl of cell lysate and 100 μl of luciferase assay
reagent (Promega). Luciferase activity was measured with
a 10 s delay and 30 s integration time and was normalized
to β-galactosidase or Renilla luciferase activity to deter-
mine transfection efficiency. The values shown represent
an average of three independent transfections and each
transfection was carried out in triplicate.
Statistical analysis
Data were expressed as means ± standard deviation of three
independent experiments. Statistical comparisons of the
results were made using analysis of variance (ANOVA).
Significant differences were established at p ≤ 0.05.
Results
Cytotoxicity of pinocembrin to Y-79 cells
In this study, we first examined the effect of pinocembrin
on cell cytotoxicity in Y-79 cells. As shown in Figure 1B,
pinocembrin did not affect the cell cytotoxicity of Y-79
cells at concentrations ranging from 0–5 μM. In order to
verify this, the dose range was applied in all subsequent
experiments to avoid the influence of cell growth and
cytotoxicity on the observed papameters, and a series of
studies were performed to measure the cell growth and
cytotoxicity upon pinocembrin stimulation. Firstly, the
effects of pinocembrin on Y-79 cell-cycle progression were
measured by flow cytometry (Figure 1C) which revealed
that a treatment with 5 μM pinocembrin had no effect
on the cell-cycle distribution for 24 h. At higher concen-
trations (10, 20, 40, 60, 80 and 100 μM), pinocembrin
increased the G1 fraction (from 60.26% to 73.57%), and
caused an apparent accumulation of the cells in the
sub-G1 phase, while decreasing the S fraction in a
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strated that a 24 h treatment of pinocembrin at a con-
centration ranging from 0 to 5 μM had no cytotoxicity
to Y-79 cells. Also, as illustrated in Figure 1D, in the
presence of TGF-β1, pinocembrin at a concentration of
5 μM did not have any toxic effects on cell viability. Thus,
non-cytotoxic concentrations of pinocembrin (0–5 μM)
were used in subsequent experiments.
Pinocembrin suppresses TGF-β1-induced cell-matrix
adhesion, invasion, migration, and epithelial-
mesenchymal transition in Y-79 cells via αvβ3 integrin
Previous studies have shown that TGF-β1 affects cells
invasion and migration through αvβ3 integrin signaling
[29]. Therefore, we hypothesized that the αvβ3 integrin
signaling pathway may be involved in TGF-β1-inducedFigure 2 The inhibitory effect of pinocembrin on TGF-β1-induced cell-m
transition of Y-79 cells involves activation of αvβ3 integrin. (A) Y-79 cells w
nM cyclic RGD peptide (cyclo-RGDfV) for 30 min and then stimulated with 10 n
and were then subjected to analyses for cell-matrix adhesion as described in M
monoclonal antibody (mAb) or 80 nM cyclic RGD peptide (cyclo-RGDfV) for 30
absence of 5 μM pinocembrin for 24 h. Then invasion assay were measured by
with matrigel. After 8 h incubation, cells on the bottom side of filter were fixed
for 6 h with polycarbonate filters. After 6 h incubation, cells on the bottom side
TGF-β1 (10 ng/ml) in the absence or presence of 5 μM pinocembrin for 0, 30, 6
by Western blotting with anti-E-cadherin, anti-N-cadherin, anti-vimentin, and an
SD of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 compcell-matrix adhesion, invasion, and migration of Y-79 cells.
Firstly, to investigate whether low-cytotoxic pinocembrin
inhibits the TGF-β1-induced adhesive properties of Y-79
cells, a cell-matrix adhesion assay was examined. As
shown in Figure 2A, treatment of Y-79 cells with TGF-β1
(10 ng/ml) induced cell adhesion. In particular, 5 μM
pinocembrin inhibited the TGF-β1-induced cell adhesion
of Y-79 cells by 47.3%. Y-79 cells were pretreated with
5 μg/ml anti-αvβ3 monoclonal antibody (mAb) or 80 nM
cyclic RGD peptide (cyclo-RGDfV) for 30 min and then
stimulated with 50 ng/ml TGF-β1 in the presence or
absence of 5 μM pinocembrin for 24 h. The pretreatment
of Y-79 cells with anti-αvβ3 monoclonal antibody or cyclic
RGD peptide decreased the TGF-β1-induced cell adhesion
by 39.7% or 49.3%, respectively. Also, the combining treat-
ment with anti-αvβ3 monoclonal antibody or cyclic RGDatrix adhesion, invasion, migration, and epithelial-mesenchymal
ere pretreated with 5 μg/ml anti-αvβ3 monoclonal antibody (mAb) or 80
g/ml TGF-β1 in the presence or absence of 5 μM pinocembrin for 24 h,
ethods. (B) In invasion assay, cells were pretreated with 5 μg/ml anti-αvβ3
min and then stimulated with 10 ng/ml TGF-β1 in the presence or
transwell for 8 h; polycarbonate filters (pore size, 8 μm) were precoated
, stained, and counted. (C) In migration assay were measured by transwell
of filter were fixed, stained, and counted. (D) Cells were pre-treated with
0, 120, 180 min, and then used to the cell-lysate extracts were measured
ti-β-actin antibodies as described in Methods. Values represent mean ±
ared with the TGF-β1 treatment only).
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adhesion by 75% or 75.7%, respectively, as compared with
that of TGF-β1 treatment only. The cyclic RGD peptide
(cyclo-RGDfV) has been demonstrated to bind αvβ3 at
high affinity and block its function effectively at low
concentrations. Furthermore, we examined the effect of
pinocembrin on Y-79 cell invasion and migration. As
shown in Figure 2B and C, the cells were treated with
5 μM pinocembrin, the results showed that the cell
invasion and migration of TGF-β1-induced Y-79 cells
was significantly decreased, compared to the TGF-β1
treatment only. Pretreatment of cells for 30 min with
5 μg/ml anti-αvβ3 monoclonal antibody or 80 nM cyclic
RGD peptide all markedly inhibited TGF-β1-induced cell
invasion and migration. Also, the combining treatment
with anti-αvβ3 monoclonal antibody or cyclic RGD
peptide and pinocembrin reduced TGF-β1-induced cell
invasion and migration by 64.3% or 70.3% and 65.7% or
74.0%, respectively, as compared with that of TGF-β1
treatment only. Epithelial-mesenchymal transition (EMT)
is a crucial progression in the development of invasive
cancer cells. We assessed the effect of pinocembrin on
EMT markers. Pinocembrin treatment increased E-cad-
herin levels and decreased vimentin and N-cadherin by
TGF-β1 stimulation (Figure 2D). Taken together, theseFigure 3 The inhibitory effect of pinocembrin on TGF-β1-induced integ
and then incubated in the different concentrations of pinocembrin (0, 1,
pretreated with TGF-β1 (10 ng/ml) and then incubated in 5 μM pinocem
then the integrins were analyzed. (C) The expressions of integrins were d
three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 comparresults suggest that inhibition of TGF-β1-induced cancer
adhesion, invasion, and migration of highly metastatic
Y-79 cells by pinocembrin may occur via activation of
the αvβ3 integrin receptor.
Pinocembrin suppresses TGF-β1-induced integrin levels in
Y-79 cells
Integrins link the ECM to intracellular cytoskeletal struc-
tures and signaling molecules and are implicated in the
regulation of a number of cellular processes, including
adhesion, signaling, motility, survival, gene expression,
growth, and differentiation [30]. Here we explored the
effect of pinocembrin on TGF-β1-induced integrin ex-
pressions in Y-79 cells. Firstly, cells were pre-treated
with TGF-β1 (10 ng/ml) and then incubated in different
concentrations of pinocembrin (0, 1, 2.5, and 5 μM) for
6 h. As shown in Figure 3A, pinocembrin significantly
inhibited the TGF-β1-induced expression levels of αν
and β3 integrin in Y-79 cells. Furthermore, cells were
pre-treated with TGF-β1 (10 ng/ml) and then incubated
in 5 μM pinocembrin for different lengths of time (0,
30, 60, 120, and 180 mins). The subsequent time course
experiment showed that the reduction of αν and β3
integrin expressions by pinocembrin also occurred in a
time-dependent manner when pinocembrin was at 5 μΜrin levels in Y-79 cells. (A) Cells were pretreated with TGF-β1 (10 ng/ml)
2.5, and 5 μM) for 6 h, and the integrins were analyzed. (B) Cells were
brin for different lengths of time (0, 30, 60, 120, and 180 mins), and
etermined by flowcytometry. Values are expressed as mean ± SD of
ed with the 0 h-treated time.
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that pinocembrin decreased the TGF-β1-induced the
expression of ανβ3 integrin (Figure 3C).
Pinocembrin suppresses TGF-β1-induced expressions of
MMP-2 and MMP-9 in Y-79 cells
To investigate the inhibitory effect of pinocembrin on
TGF-β1-induced MMP-2 and MMP-9 enzyme activities,
gelatin zymography was performed to examine the activities
of MMP-2 and MMP-9 using conditioned medium, which
was collected and measured after TGF-β1 stimulation with
or without pinocembrin treatment. Both MMP-2 and
MMP-9 were detected in the conditioned media of Y-79Figure 4 The inhibitory effect of pinocembrin on TGF-β1-induced activi
serum-free medium were pretreated with TGF-β1 (10 ng/ml) and then incuba
(A) The conditioned media were collected and MMP-2/-9 activities were dete
were analyzed by Western blotting. (C) The MMP-2/-9 mRNA expressions wercells, while TGF-β1 significantly increased the MMP-2
and MMP-9 activities. Also, pinocembrin inhibited the
MMP-2 and MMP-9 activities stimulated by TGF-β1 in a
dose-dependent manner (Figure 4A). The zymography
result obtained was further confirmed by Western blotting
analysis. As shown in Figure 4B, treatment with 1 μM
pinocembrin reduced the protein expression levels of
MMP-2 or MMP-9 induced by TGF-β1, while 5 μM
pinocembrin significantly inhibited the TGF-β1-induced
protein expression levels of MMP-2 or MMP-9. To deter-
mine whether the inhibition of MMP-9 or MMP-2 protein
expressions by pinocembrin was due to a decreased level of
transcription, we performed RT-PCR and observed mRNAties and expressions of MMP-2/-9 in Y-79 cells. The cultured cells in
ted in the different concentrations of pinocembrin (0, 1, 2.5, and 5 μM).
rmined by gelatin zymography. (B) The MMP-2/-9 protein expressions
e analyzed by RT-PCR. β-Actin and GADPH was used as internal controls.
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pinocembirn reduces the TGF-β1-induced MMP-2 and
MMP-9 mRNA expressions of Y-79 cells in a dose-
dependent manner. The data suggest pinocembrin prevents
the transcription of MMP-2 and MMP-9 in response to
TGF-β1. These results suggested that the anti-metastatic
effect of pinocembrin is related to the inhibition of the
enzymatically degradative processes of tumor metastasis.
Pinocembrin inhibits TGF-β1-induced phosphorylation of
FAK/p38α in Y-79 cells
In many signaling milieus, the FAK signaling during
adhesion has been shown to be capable of regulating
integrin-mediated signaling and involved in cell metastasis,
but the mechanism underlying its activity is only partly
understood. To investigate proteins whether could poten-
tially phosphorylate, we performed a time-course assay of
the inhibitory effect of pinocembrin on the expressions of
non-Smad (FAK/MAPK) and Smad signaling pathways by
TGF-β1-induced to clarify the underlying mechanisms. As
shown in Figure 5A, pinocembrin decreased the TGF-β1-
induced the phosphorylation of FAK at the Tyr 397, 576,
and 925 sites in Y-79 cells. However, pinocembrin did not
cause any change in the total protein levels of total FAK. In
addition, the MAPK family is also a target of FAK signal-
ing, and hence we next investigated the phosphorylation of
JNK, p38α and ERK1/2 in Y-79 cells. The data showed that
pinocembrin decreased the TGF-β1-induced the phosphor-
ylation of p38α, but not phospho-JNK and phospho-ERK in
Y-79 cells. Moreover, we found that pinocembrin was unable
to cause any significant deviation in the ratio of phospho-
Smad2 to total Smad2 at any measure time (Figure 5B).
Total protein levels of JNK, ERK, p38α and Smd2 did not
change with TGF-β1 and pinocembrin treatment.Figure 5 The inhibitory effect of pinocembrin on TGF-β1-induced pho
pretreated with TGF-β1 (10 ng/ml) for 2 h and then incubated in 5 μM pin
levels of FAK (Tyr397, Tyr576, Tyr925), Smad2, JNK1/2, ERK1/2, p38α were mPinocembrin inhibits TGF-β1-induced DNA binding activity
of NF-κB and the expressions of NF-κB and IκBα in Y-79 cells
The expressions of MMP-2 and MMP-9 genes are regu-
lated through the transcriptional level interaction of
NF-κB with their binding sequences in MMP-2 and
MMP-9 gene promoters. NF-κB, one of the main molecu-
lar targets of chemopreventive phytochemicals [31], is a
transcription factor involved in multiple cellular processes,
including cytokine gene expression, cellular adhesion,
apoptosis, and metastasis [32]. These inflammatory meta-
static mediators were found to be altered by pinocembrin
treatment. Therefore, we used transcriptional activation
assays to determine whether pinocembrin affects NF-κB
dependent transcription. Stimulation with TGF-β1 resulted
in an approximately 5-fold increase in luciferase activity,
and the TGF-β1-induced NF-κB activity was inhibited
by pinocembrin treatment in a time-dependent fashion
(Figure 6A). The p65 and p50 subunits of NF-κB have been
demonstrated to exert critical activity in the transcription
of MMP-2/MMP-9 genes. Moreover, the activation of
NF-κB occurs through the phosphorylation of IκBα
releasing the NF-κB for nuclear translocation and thus
binding to the promoter sites of target genes. Therefore, we
also performed a Western blot assay to detect expressions
of NF-κB (p65 and p50) and IκBα to clarify the inhibitory
action of pinocembrin. As shown in Figure 6B, pre-
treatment of the cells with 5 μM pinocembrin for 9 h
significantly inhibited both IκBα degradation and NF-
κB (p50/p65) nuclear translocation. Because TGF-β1-
stimulated activation of NF-κB is correlated with IκBα
degradation, pinocembrin blocked TGF-β1-induced IκBα
degradation by inhibiting phosphorylation of IκBα. To
further determine the possibility of NF-κB binding to
MMP-2/MMP-9 promoter binding sites, EMSA was donesphorylation of FAK/p38α in Y-79 cells. (A and B) Cells were
ocembrin for 0, 1, 2, 3, and 6 h. The total protein and phosphorylation
easured by Western blotting. β-Actin was used as an internal control.
Figure 6 The inhibitory effect of pinocembrin on TGF-β1-induced NF-κB transcriptional activity/expressions of NF-κB/IκBα phosphorylation
and degradation in Y-79 cells. (A) Cells were pretreated with TGF-β1 (10 ng/ml) for 2 h and then treated with 5 μM pinocembrin for 0, 1, 2, 3, and 9 h,
and the NF-κB transcriptional activity by luciferase report gene assays, as described in Methods. (B) Nuclear extracts were subjected to SDS–PAGE followed
by Western blotting with specific antobodies (anti-NF-κB p50, anti-NF-κB p65, anti-p-IκBα, anti-IκBα). C23 and β-actin were used as internal control. (C) NF-
κB DNA-binding activity by EMSA, as described in Methods. Lane 1: nuclear extracts incubated with 100-fold excess unlabeled consensus oligonucleotide
(comp.) to confirm the binding specificity. Lane 2 represents nuclear extract from Y-79 cells in the absence of TGF-β1 (negative control). Values represent
mean ± SD of three independent experiments. (*p< 0.05, **p< 0.01, ***p< 0.001 compared with the TGF-β1 treatment only).
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TGF-β1-stimulated NF-κB DNA binding activities were
strongly inhibited by pinocembrin at the concentration
of 5 μM.
Discussion
Retinoblastoma is the most common primary intraocular
tumor in children (0–5 years). It is associated with gener-
ally poor prognosis due to its tendency toward local inva-
sion and subsequent metastasis. Recently, antimetastatic
agents have been defined as a new class of cancer chemo-
preventive agent. Pinocembrin is one of the flavonoids
with the highest concentration levels in propolis. Flavo-
noids are a vast group of heterogeneous polyphenols that
are thought to have positive effects on human health,
including cancer prevention. Various studies have shown
that pinocembrin exerts pleiotropic anticancer effects,including preventive, anticarcinogenic, and antiproliferative
effects in various in vivo and in vitro models. In particular,
pinocembrin could influence several processes and play
important roles in the regulation of various molecular
targets, including NF-κB [33], Smad2 and PPARγ tran-
scription factors [34], Vascular endothelial growth factors
[35], TGF-β1 [34], necrosis factor-alpha, interleukin-1beta,
intercellular adhesion molecule-1, vascular cell adhesion
molecule-1 inflammatory cytokines [36], p38 MAPK [37],
ERK1/2 and PI3K/Akt protein kinases [38] and other
enzymes (COX-2 and MMPs) [39,36].
Tumor promoting activity of TGF-β1 associated with
the induction of EMT has been documented for different
tumor types [40]. Several reports have shown that TGF-β1
has been identified as the main inducer of tumor EMT.
The EMT induced by TGF-β1 results in the disruption of
the polarized morphology of epithelial cells, formation
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[41]. The TGF-β1 family of secreted factors is involved in
controlling different biological processes, including cell
proliferation, differentiation, and apoptosis. Furthermore,
conjunction between TGF-β1 signaling and carcinoma
cells in cell invasiveness and tumor metastasis has recently
been reported [42]. These effects of TGF-β1 are related to
its ability to induce EMT and stimulate cell migration.
Furthermore, several non-Smad pathways have also been
shown to mediate the cellular effects of TGF-β1. These
include ERK, JNK, p38 MAPK, and PI3K/Akt. In this
study, we have demonstrated that pinocembrin suppresses
TGF-β1-induced EMT via the p38α signaling pathway.
We further examined the effect of the expression levels
of E-cadherin, N-cadherin, and vimentin. E-cadherin, an
adherent junction protein and type I transmembrane
glycoprotein, plays a pivotal role in the maintenance of
normal tissue architecture and the suppression of cancer
invasion [43]. A previous study demonstrated that the loss
of E-cadherin-mediated adhesion plays an important role
in the transition of epithelial tumors from a benign to an
invasive state [44]. More recent evidence indicates that
the gain of expression of another adhesion molecule, N-
cadherin, is associated with heightened invasive potentialFigure 7 Proposed mechanisms by which pinocembrin suppresses TG
in human Y-79 cells. Pinocembrin inhibits TGF-β1-acted through avβ3 integ
of IκBα, activation of NF-κB (p50 and p65), nuclear translocation, NF-κB bindin
gene expressions, and contributing to the inhibition of cell EMT and metastasin tumor cells. N-cadherin has also been reported to
induce a mesenchymal-scattered phenotype associated
with reduced E level in a squamous cell carcinoma cell
line [45]. Vimentin, a mesenchymal marker, has been was
observed in a few cancer cells. It has previously been
demonstrated that vimentin expression is substantially
increased in cancer cells of hepatic metastasis [46]. Taken
together, our results are consistent with the notion that
the changes were associated with an increase in E-
cadherin expression and a reduction in N-cadherin and
vimentin in TGF-β1-treated Y-79 cells. Loss of cell-cell
adhesion followed by the dissociation of epithelial struc-
tures is a prerequisite for increased cell motility and
tumor invasion. These findings raise the possibility that
N-cadherin and vimentin contribute directly to the invasive
phenotype. In addition to promoting motile and invasive
activities of Y-79 cells in vitro, the expressions of N-
cadherin and vimentin greatly sensitized Y-79 cells to
TGF-β1, stimulating marked increases in cell migration
and invasion as well as in MMP-2/-9 production. When
Y-79 cells were treated with pinocembrin, there dramatic-
ally reduced the activities and expressions of MMP-2/-9.
It is of importance to note that MMP-2/-9 plays roles in
tumor progression, as over-expression of the MMP-2/-9F-β1-induced epithelial-mesenchymal transition and metastasis
rin receptor to activate FAK and p38α, leading to the phosphorylation
g to MMP-2/MMP-9 promoter binding sites, initiation of MMP-2/MMP-9
is.
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a breast cancer model [47]. Also, Sasaki et al. [48] reported
that the survival rates of lung cancer patients were poor
for those patients with an elevated MMP-2/-9 mRNA
expression on the tumor tissue. We have demonstrated
that reduction of proteolytically active MMP-2/-9 is
involved in pinocembrin mediated-cell invasion and
migration. In addition, the transcription of the MMP-
2/-9 gene is regulated by upstream sequences, including
motifs corresponding to the NF-κB binding element
[49,50]. Here, we also found that pinocembrin inhibits
MMP-2/-9 expression through preventing IκBα being
phosphorylated and enhancing IκBα protein expression,
both leading to inactivation of NF-kB DNA binding
activity. A comprehensive analysis of MMP-2/-9 expres-
sion in Y-79 cells will be necessary to fully understand
the biological properties of Y-79 cells and to promote
the development of new therapeutic strategies.Conclusions
In view of these previous findings, we proposed a sche-
matic presentation of possible mechanisms for the anti-
metastatic activity of pinocembrin could effectively
inhibit TGF-β1-induced EMT and metastasis of Y-79 cells
by decreasing MMP-2 and MMP-9 expressions through
the αvβ3 integrin receptor and FAK/p38α/NF-κB signaling
pathway (Figure 7). Based on our findings, we suggest that
pinocembrin promotes a strong protective effect against
TGF-β1-mediated metastasis via down-regulation of early
and long-term inside-out signaling processes. The findings
and concepts disclosed here provide an important basis
for a further exploration of the action mechanisms of
pinocembrin and its potentially beneficial effect in the
prevention of tumor metastasis.
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